Artisan Partners Limited Partnership Has $21.49 Million Stock Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI)

Artisan Partners Limited Partnership decreased its stake in Denali Therapeutics Inc. (NASDAQ:DNLI) by 3.3% in the fourth quarter, HoldingsChannel reports. The firm owned 1,054,523 shares of the company’s stock after selling 36,495 shares during the period. Artisan Partners Limited Partnership’s holdings in Denali Therapeutics were worth $21,491,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the stock. Vanguard Group Inc. lifted its stake in Denali Therapeutics by 7.6% during the fourth quarter. Vanguard Group Inc. now owns 12,021,230 shares of the company’s stock valued at $244,993,000 after buying an additional 843,996 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of Denali Therapeutics by 9.2% in the 3rd quarter. Wellington Management Group LLP now owns 10,727,450 shares of the company’s stock valued at $312,491,000 after acquiring an additional 903,683 shares in the last quarter. FMR LLC lifted its position in shares of Denali Therapeutics by 3,234.3% in the 3rd quarter. FMR LLC now owns 7,831,378 shares of the company’s stock valued at $228,128,000 after acquiring an additional 7,596,508 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Denali Therapeutics by 63.2% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,749,486 shares of the company’s stock worth $109,223,000 after purchasing an additional 1,451,770 shares during the period. Finally, Principal Financial Group Inc. grew its position in Denali Therapeutics by 13.8% during the 3rd quarter. Principal Financial Group Inc. now owns 1,238,476 shares of the company’s stock worth $36,076,000 after purchasing an additional 149,939 shares in the last quarter. Hedge funds and other institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Price Performance

Denali Therapeutics stock opened at $14.78 on Friday. Denali Therapeutics Inc. has a one year low of $13.67 and a one year high of $33.33. The company’s fifty day moving average price is $19.05 and its two-hundred day moving average price is $23.25. The company has a market capitalization of $2.15 billion, a price-to-earnings ratio of -5.36 and a beta of 1.46.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.67) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.08. As a group, sell-side analysts anticipate that Denali Therapeutics Inc. will post -2.71 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on DNLI shares. The Goldman Sachs Group decreased their target price on Denali Therapeutics from $45.00 to $40.00 and set a “buy” rating for the company in a research report on Tuesday, January 28th. Oppenheimer lowered their target price on Denali Therapeutics from $50.00 to $42.00 and set an “outperform” rating on the stock in a research note on Monday, March 3rd. Robert W. Baird initiated coverage on shares of Denali Therapeutics in a research report on Tuesday, January 7th. They issued an “outperform” rating and a $31.00 price target for the company. HC Wainwright raised their price target on shares of Denali Therapeutics from $80.00 to $87.00 and gave the stock a “buy” rating in a report on Friday, February 28th. Finally, Bank of America dropped their price objective on shares of Denali Therapeutics from $30.00 to $28.00 and set a “buy” rating on the stock in a research note on Monday, March 10th. Two research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Denali Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $37.20.

Insider Activity

In related news, Director Steve E. Krognes sold 3,339 shares of Denali Therapeutics stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $20.81, for a total value of $69,484.59. Following the transaction, the director now owns 25,757 shares in the company, valued at $536,003.17. This trade represents a 11.48 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Ryan J. Watts sold 29,266 shares of the company’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $20.22, for a total transaction of $591,758.52. Following the sale, the chief executive officer now owns 260,721 shares of the company’s stock, valued at $5,271,778.62. This trade represents a 10.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 47,940 shares of company stock valued at $973,442 over the last 90 days. 7.90% of the stock is currently owned by company insiders.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.